Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Indocin — INDOCIN SR
Application NDA018185 (NDA)
Oraverse — REGITINE
Application NDA008278 (NDA)
Indocin — INDOCIN
Application NDA016059 (NDA)
Indocin — INDOMETHACIN
Application NDA018806 (NDA)
Indocin — INDOCIN
Application NDA017814 (NDA)
Indocin — INDOMETHACIN
Application NDA018829 (NDA)
Indocin — INDOMETHACIN
Application NDA018690 (NDA)
Indocin — INDOMETHACIN
Application NDA018851 (NDA)
Indocin — INDOMETHACIN
Application NDA018730 (NDA)
Indocin — INDOMETHACIN
Application NDA018858 (NDA)
Indocin — INDOCIN
Application NDA018332 (NDA)
Indocin — INDOCIN
Application NDA018878 (NDA)
Clozaril — CLOZARIL
Application NDA019758 (NDA)
Clozaril — FAZACLO ODT
Application NDA021590 (NDA)
Oraverse — ORAVERSE
Application NDA022159 (NDA)
Indocin — INDOMETHACIN
Application NDA022536 (NDA)
Clozaril — VERSACLOZ
Application NDA203479 (NDA)
Indocin — TIVORBEX
Application NDA204768 (NDA)
Oraverse — RYZUMVI
Application NDA217064 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)